A Study to Explore the Safety, Tolerability, Pharmacokinetic Profile, and Potential Efficacy of Guanabenz in Patients With Early-Childhood Onset Vanishing White Matter (VWM)
This research study is investigating a potential new treatment called Guanabenz for a serious brain condition in children known as Vanishing White Matter (VWM). The main aims are to understand if it's safe to use, how the body processes the medication, and whether it shows any promise in helping those with the condition. This particular study is an early-stage trial, combining Phase I and Phase II. This means scientists are gathering initial information about the drug's safety and how different doses affect patients. They will be closely monitoring for any side effects and looking at how the drug behaves in the body, as well as observing any potential positive effects on the brain and overall health.
At a glance
What is this study about?
This study is about a medication called Guanabenz, which is being tested for a very rare and serious brain condition in children called Vanishing White Matter (VWM). VWM is a progressive disease that affects the brain's white matter, which is crucial for communication between different parts of the brain. There currently aren't many treatments for VWM, so finding new options is really important.
Researchers are conducting what's called a 'Phase I and Phase II' study. In simple terms, this means they are looking at two main things: firstly, they want to make sure the medicine is safe and find the right dose. This involves carefully watching for any side effects. Secondly, they want to see how the body handles Guanabenz – how it's absorbed, used, and cleared from the body. They will also be looking for any early signs that the medicine might be making a positive difference to the patients or their condition.
To do this, they will be giving different strengths of Guanabenz capsules and closely monitoring the children. This includes checking for any changes in their health, taking blood samples to measure the drug levels, looking at detailed brain scans (MRI), and observing overall how the children are doing. The goal is to gather crucial information to decide if Guanabenz could become a helpful treatment for VWM in the future.
Key takeaways
- This study is testing a potential new drug, Guanabenz, for Vanishing White Matter (VWM).
- It's an early-stage study focusing on safety, how the body handles the drug, and early signs of it working.
- Children with VWM of any age and gender can be considered.
- Participation involves regular clinic visits, blood tests, and brain scans (MRI).
- There are potential benefits and risks, and you can withdraw at any time.
Who may be eligible?
This study is open to both boys and girls of all ages who have been diagnosed with Vanishing White Matter (VWM). The doctors will need to confirm the specific type of VWM.
Before anyone can join, a medical team will carefully check to make sure it's suitable and safe for them to take part. This will involve reviewing their medical history and current health.
Other specific health requirements, which will be discussed in detail by the study team, may also need to be met. It is important to ask all your questions to the study doctors to understand if this study is right for your child.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Does my child have a confirmed diagnosis of Vanishing White Matter (VWM)?
- Is my child of any age, and are they male or female?
- Am I able to commit to regular clinic visits for my child?
- Am I comfortable with my child having blood tests and brain scans?
- Are there any other serious health conditions my child has that might affect participation?
What does participation involve?
If your child takes part in this study, they will receive Guanabenz capsules in different strengths. The study team will decide the specific dose.
You will need to attend regular visits to the study clinic. During these visits, the doctors will perform health checks, which might include physical examinations, blood tests, and detailed brain scans (MRIs). They will also ask about any changes in your child's health or any effects they might be experiencing.
Throughout the study, any health concerns will be carefully monitored. The total duration of participation in this study, including all follow-up, will be explained by the study team, but it will involve ongoing assessments from the start of treatment until the study concludes.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is Vanishing White Matter (VWM)?
VWM is a rare, inherited brain disease that gradually destroys the brain's white matter, which is important for communication between different brain areas. This leads to worsening neurological problems over time.
What is Guanabenz?
Guanabenz is a medicine being tested to see if it can help treat VWM. It's currently being studied to understand its safety, how the body uses it, and if it might have any positive effects on the condition.
What does 'Phase I and Phase II (Integrated)' mean?
This means the study combines two early stages of drug testing. Phase I focuses on safety and finding the right dose, while Phase II looks for early signs that the drug might be effective and continues to monitor safety.
Will my child definitely receive the study drug?
Yes, if your child is eligible and joins this study, they will receive Guanabenz in capsule form, in specific dosages determined by the study protocol.
How long will my child be in the study?
The exact length of time will be discussed by the study team, but participation will involve ongoing monitoring and visits from the start of treatment until the study concludes, which can be several months or longer.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.